What are the top healthcare AI startups by total funding raised?

Top startups in the Healthcare AI ranked by total funding raised

Here is an updated table that ranks the top startups in the Healthcare AI based on the total amount of funding they have raised to date.

The table also includes the total number of funding rounds, the date and size of the latest round, the financing type (e.g. Series A, equity financing), key investors, the startup’s current status (active, IPO, acquired, or shut down), and a confidence score based on the data collected (we excluded startups with very low data confidence, to make sure everything is reliable).

If you need to dig deeper and get more detailed data, please check our report covering the Healthcare AI.

Isomorphic Labs is now the most heavily funded Healthcare AI company we found, with roughly $2.7 billion in disclosed external equity funding after its latest $2.1 billion round.

That new financing changes the top of the ranking quite dramatically. Relay Therapeutics has raised about $1.7 billion across private and public equity financings, while XtalPi and Freenome are around $1.3 billion in our reconstruction. Tempus is around $1.2 billion. Xaira Therapeutics launched with roughly $1 billion, and Commure has also moved into the billion-dollar range depending on which historical financings are included.

The mix is revealing. Isomorphic Labs, Relay, XtalPi and Xaira are largely drug-discovery businesses. Freenome and Tempus sit closer to diagnostics and precision medicine. Commure operates healthcare workflow infrastructure. The companies raising the most money are solving very different problems, with very different capital needs.

Company	Approx. disclosed equity funding	Main focus	Status
Isomorphic Labs	~$2.7B	AI drug design	Private
Relay Therapeutics	~$1.7B	Computational drug discovery	Public
XtalPi	~$1.3B	AI drug discovery and automation	Public
Freenome	~$1.3B	Blood-based cancer detection	Public
Tempus AI	~$1.2B	Precision medicine and diagnostics	Public
Commure	~$1B+	Healthcare operations AI	Private
Xaira Therapeutics	~$1.0B	AI-native drug development	Private
AbCellera	~$945M	Antibody discovery	Public
Exscientia	~$879M	AI drug discovery	Acquired
Olive AI	~$840M+	Healthcare administration automation	Shut down

Did Isomorphic Labs just become the most funded Healthcare AI company?

Yes. Isomorphic Labs has jumped to roughly $2.7 billion in external funding, putting it comfortably ahead of every other Healthcare AI company in our research.

The company first raised $600 million from Thrive Capital, GV and Alphabet. It then followed with a $2.1 billion Series B led by Thrive, joined by Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund.

The scale is unusual even for AI biotech. That latest round alone was larger than the entire lifetime funding of Relay Therapeutics, Xaira Therapeutics, Abridge, OpenEvidence or almost any other company in this market.

Isomorphic is using the money to expand its AI drug-design engine and advance its own therapeutic programs. The company is moving further from providing drug-discovery technology to pharmaceutical partners and deeper into the expensive process of developing medicines itself.

How much funding has Relay Therapeutics raised?

Relay Therapeutics has raised roughly $1.7 billion in equity financing, making it one of the most heavily financed AI drug-discovery companies even after Isomorphic Labs moved ahead.

Relay’s funding story stretches across private venture rounds, its IPO and subsequent public offerings. Most recently, the company raised approximately $316 million in gross proceeds from a follow-on offering after underwriters exercised their full option.

Its financial position shows what that financing means in practice. Relay reported about $911 million in cash, cash equivalents and investments after the offering, enough, according to management, to fund operations into 2029.

One quirk in the ranking is that Relay is a public biotech company today. Its $1.7 billion total is useful when measuring cumulative equity capital raised, but it should not be read as $1.7 billion of venture capital.

Which private Healthcare AI startups have raised the most funding?

Isomorphic Labs leads private Healthcare AI by a huge margin, while Xaira Therapeutics, Commure, Abridge and OpenEvidence form the next group of unusually well-funded private companies.

Xaira started with roughly $1 billion. Commure has reached around the billion-dollar level across its funding history. Abridge has raised roughly three-quarters of a billion dollars, while OpenEvidence says it has raised close to $700 million in about a year.

The differences between them are almost as interesting as the totals. Isomorphic and Xaira need capital for drug programs that can take years to reach patients. Abridge and OpenEvidence sell software into healthcare and can generate commercial revenue much earlier. Commure sits somewhere between conventional software and a broader healthcare operating platform. Drug programs that take years to earn anything and software that sells right away are different business models, which we compare in our market report about healthcare AI.

Once we isolate private companies, the ranking is less distorted by IPO proceeds, but it still mixes businesses with radically different cash requirements.

Why do AI drug-discovery startups raise so much money?

AI drug-discovery startups raise the biggest rounds in Healthcare AI because they have to pay for both sophisticated AI infrastructure and the expensive work of developing actual medicines.

Isomorphic Labs raised $2.1 billion in one round. Xaira launched with roughly $1 billion. Chai Discovery recently raised $400 million, Formation Bio raised $372 million and Pathos AI raised $365 million. Generate:Biomedicines raised $273 million in its Series C.

Those checks look enormous next to most healthcare software rounds, but drug development burns capital differently. Once an AI biotech owns therapeutic programs, it needs laboratories, scientists, preclinical studies, manufacturing work, regulatory preparation and eventually clinical trials. A successful molecule can still take years before producing revenue.

That is why the funding leaderboard leans so heavily toward biotech. Investors are financing long development pipelines, not simply larger engineering and sales teams.

AI drug company	Major round	Amount
Isomorphic Labs	Series B	$2.1B
Xaira Therapeutics	Launch financing	~$1.0B
Chai Discovery	Series C	$400M
Formation Bio	Series D	$372M
Pathos AI	Series D	$365M
Generate:Biomedicines	Series C	$273M
Genesis Therapeutics	Series B	$200M
Exscientia	IPO financing	$160M+

Did Xaira Therapeutics really raise $1 billion in one round?

Yes. Xaira Therapeutics launched with close to $1 billion of committed capital, an extraordinary amount for a company essentially starting from day one.

ARCH Venture Partners and Foresite Labs created the company with backing from investors including F-Prime and several major institutional funds. Rather than starting with a $20 million or $50 million early-stage round and raising progressively larger rounds later, Xaira was financed from the beginning to build a large AI-and-biotech organization.

The company combines machine learning, large biological datasets and experimental biology with an internal drug-development effort. That requires far more upfront capital than a typical software startup.

Xaira reached the billion-dollar funding club through one giant launch rather than a decade of fundraising. Very few Healthcare AI companies have followed anything close to that path.

How much money has Abridge raised?

Abridge has raised roughly $750 million and has become one of the best-funded clinical AI companies outside drug discovery.

The pace has been fast. Abridge raised a $30 million Series B, followed by a $150 million Series C, a $250 million Series D and a $300 million Series E. Those last three rounds alone added $700 million.

The fundraising has come with a sharp rise in deployment. Abridge now says more than 300 enterprise health systems have adopted its technology, representing more than 250 million patients. The company expects its platform to support more than 100 million patient-clinician conversations over the year.

A very recent development gives that scale another dimension: Abridge was selected as an eligible provider under the U.S. Department of Veterans Affairs' nationwide ambient-AI enterprise contract. The contract has a ceiling of $775.72 million across all participating vendors, so that figure should not be confused with revenue awarded to Abridge. Still, the company is already operational across more than 75 VA medical centers.

Why is so much funding going into ambient clinical AI?

Ambient clinical AI is attracting hundreds of millions of dollars because hospitals are moving quickly from small documentation pilots to large enterprise deployments.

Abridge raised $550 million across its Series D and Series E. Ambience Healthcare added a $243 million Series C. Nabla raised $70 million in its Series C, while Suki, Corti, DeepScribe and several others have also attracted meaningful funding.

The products are getting broader too. Abridge has expanded beyond medical notes into coding, decision support and other clinical workflows. Ambience combines documentation with coding and clinical documentation integrity. Tandem Health is extending its product from an AI medical assistant toward what it calls an AI-native clinic operating system. Tools that grow from note-taking into coding and clinic operations blur the edges of the market, and we mark what counts in our report on healthcare AI.

The wider scope helps explain the money flowing into the category these days. Investors are increasingly betting that one of these products can become a core workflow layer inside a health system rather than remain a clever transcription tool.

Is OpenEvidence now one of the most funded Healthcare AI startups?

Yes. OpenEvidence has raised nearly $700 million and reached the top tier of private clinical AI at remarkable speed.

Its latest $250 million Series D valued the company at $12 billion. According to the company announcement, OpenEvidence went from roughly 3 million monthly clinical consultations a year earlier to about 18 million in one month, all from verified U.S. physicians.

The company also said it had passed $100 million in annual revenue after building out its commercial operation less than a year earlier. Its model is unusual because doctors can use the medical search product for free while OpenEvidence monetizes the audience commercially.

Much of its funding arrived after substantial product usage was already visible, whereas the biggest AI-biotech rounds are often financing years of development before meaningful product revenue appears.

How much funding has Commure raised?

Commure has moved into roughly billion-dollar cumulative funding territory, making it one of the largest privately financed Healthcare AI platforms.

The company recently raised another $70 million at a $7 billion post-money valuation. General Catalyst led the round, with participation from Sequoia Capital, Morgan Stanley and Kirkland & Ellis. We follow which investors lead rounds like this one, and what they back next, in our report on healthcare AI.

Commure says its technology operates inside more than 500 healthcare organizations and more than 3,000 sites of care. Its products span clinical workflows, revenue-cycle management and administrative automation, giving the company a broader footprint than most single-purpose Healthcare AI tools.

Its financing history also includes acquisitions and combinations that make simple database totals less tidy than for a newly founded startup. Our reconstruction therefore puts more weight on identifiable equity rounds than on any single published cumulative number.

What are the biggest Healthcare AI funding rounds ever?

Isomorphic Labs' $2.1 billion Series B is now the standout Healthcare AI financing, followed by Xaira Therapeutics' roughly $1 billion launch round.

After those two, there is a large drop. Isomorphic's first external raise was $600 million. Chai Discovery raised $400 million, Formation Bio $372 million and Pathos AI $365 million. Relay Therapeutics' recent public offering brought in approximately $316 million, while Abridge raised $300 million in its Series E.

The gap is huge. A $250 million financing is enormous in most startup markets; here it does not come close to the very top.

Company	Financing	Amount	Area
Isomorphic Labs	Series B	$2.1B	Drug discovery
Xaira Therapeutics	Launch financing	~$1.0B	Drug discovery
Isomorphic Labs	First external round	$600M	Drug discovery
Chai Discovery	Series C	$400M	Molecular design
Formation Bio	Series D	$372M	Drug development
Pathos AI	Series D	$365M	Oncology
Relay Therapeutics	Follow-on offering	~$316M	Drug discovery
Abridge	Series E	$300M	Clinical AI
Innovaccer	Series F	$275M	Healthcare data
Generate:Biomedicines	Series C	$273M	Protein therapeutics

Which Healthcare AI startups have raised money most recently?

Healthcare AI funding is still moving quickly, with recent large rounds appearing across drug discovery, clinical workflows, medical imaging and clinical trials.

Isomorphic Labs raised $2.1 billion, Chai Discovery raised $400 million and Aidoc raised $150 million. Tandem Health then raised a $100 million Series B, while QuantHealth raised $45 million for its clinical-trial simulation platform. Public companies including Relay Therapeutics and AbCellera have also gone back to investors for fresh equity.

Tandem is worth watching because the company says its product is already used by 10,000 care organizations across 14 European markets. Aidoc's round took its disclosed total above $500 million. Hippocratic AI, meanwhile, raised $126 million in its Series C and said the round brought cumulative funding to $404 million, higher than the total in our initial dataset.

The activity is spread across enough categories that it is hard to describe this as one narrow funding boom. Investors are still writing large checks for several different versions of Healthcare AI.

Are investors still funding AI medical imaging startups?

Yes, although medical imaging now looks like a more mature Healthcare AI category than ambient AI or generative drug design.

Aidoc remains the standout private company. Its $150 million Series E pushed total funding above $500 million. Cleerly has raised close to $400 million for coronary imaging, Exo around $320 million for handheld ultrasound and Viz.ai roughly $250 million for disease detection and care coordination.

There is also a meaningful second group: Proscia, Qure.ai, Ibex Medical Analytics, RapidAI and Ultromics have all raised substantial capital for imaging or image-based diagnostics. How imaging and diagnostics companies fall into tiers is shown on the market grids in our healthcare AI market report.

The category has already produced several acquisitions. Tempus acquired Paige, while Arterys, Caption Health, Zebra Medical Vision and Kheiron Medical Technologies also ended up inside larger companies. Medical imaging is simply further along in its lifecycle than many newer generative-AI healthcare categories.

Who are the biggest investors in Healthcare AI startups?

Thrive Capital, Andreessen Horowitz, General Catalyst, SoftBank-related funds, Sequoia and several specialist life-sciences investors keep showing up in the largest Healthcare AI rounds.

Thrive led both of Isomorphic Labs' external rounds and co-led OpenEvidence's latest financing. Andreessen Horowitz backed Abridge, Ambience Healthcare, Formation Bio and Genesis Therapeutics. General Catalyst appears around Commure, Aidoc and Hippocratic AI. Sequoia has backed companies including Commure, Chai Discovery and Formation Bio.

SoftBank or the Vision Fund has appeared around XtalPi, Tempus, Exscientia, Aidoc and Clarify Health. On the biotech side, specialist investors such as ARCH Venture Partners, Foresite, RA Capital, Perceptive Advisors and Bain Capital Life Sciences play a much bigger role.

Strategic money is common too. Alphabet and GV backed Isomorphic Labs. NVIDIA's investment arm has participated in several Healthcare AI companies, while Sanofi, Amgen, AstraZeneca and Pfizer have invested around businesses touching drug discovery or development.

The breadth is striking. The same investor can back a drug-design company, a clinical documentation product and an operational healthcare platform because all three could become important layers of the healthcare technology stack.

Do IPOs make Healthcare AI funding rankings misleading?

They can. A cumulative equity-funding ranking stays useful, but public offerings can make mature Healthcare AI companies look directly comparable with private startups when they are actually raising capital at very different stages.

Relay Therapeutics recently raised about $316 million through a follow-on offering. AbCellera raised $200 million in an oversubscribed public offering. SOPHiA GENETICS closed a $57.5 million public offering. These are legitimate equity financings and belong in a cumulative capital total.

Freenome is another good example. Its move into the public markets brought approximately $310 million in gross proceeds, including a $240 million PIPE led by Perceptive Advisors and RA Capital. The company began trading publicly after the business combination closed.

Readers looking specifically for venture-backed private startups should use the private-company comparison above. Readers asking how much equity capital a Healthcare AI business has raised over its entire life should include public-market financing as well.

Do the most funded Healthcare AI startups also have the most customers?

No. Healthcare AI funding and real-world adoption diverge sharply once we compare drug developers with clinical software companies.

Isomorphic Labs has raised roughly $2.7 billion, but that money is largely funding an AI drug-design engine and therapeutic pipeline rather than a mature commercial drug business. Xaira's roughly $1 billion launch financing follows the same broad logic.

OpenEvidence, by comparison, says doctors generated about 18 million clinical consultations on its platform in a single month and that annual revenue had passed $100 million. Abridge says its technology is used across more than 300 enterprise health systems. Tandem Health reports 10,000 care organizations in 14 European markets despite raising only a fraction of Isomorphic's total.

Funding tells us how much capital investors have committed and how expensive a company's strategy is. It tells us much less about who has already reached the most users.

What happened to Olive AI after it raised more than $800 million?

Olive AI shut down after raising more than $800 million, making it the clearest warning in the Healthcare AI funding leaderboard.

Olive raised $225 million near the end of 2020 and another $400 million only months later, at which point its valuation reached about $4 billion. Different historical totals put cumulative funding around $840 million to more than $900 million depending on which transactions are counted.

The company later cut staff, sold major business units and wound down the rest of its operations. Its clearinghouse and patient-access businesses went to Waystar, while Humata Health bought the prior-authorization business. Olive AI's unwinding invites the question of what stalled startups had in common, and we ask it in our report covering the healthcare AI market.

Keeping Olive in a historical cumulative-funding ranking is useful precisely because the company failed. Investors once committed more capital to Olive than they have to most active Healthcare AI startups today, yet that capital did not produce a durable independent company.

Which well-funded Healthcare AI startups have already been acquired?

Healthcare AI has already produced a long list of acquisitions, especially in drug discovery, medical imaging, pathology and clinical workflow software.

Exscientia is one of the largest examples. Recursion completed its combination with the company, turning Exscientia into a wholly owned subsidiary. Tempus later acquired digital-pathology company Paige for $81.25 million, mostly in Tempus stock.

Our dataset also includes Augmedix, Memora Health, Arterys, Saama, Caption Health, Zebra Medical Vision, Deep 6 AI, Ezra and Kheiron Medical Technologies among acquired companies.

The acquisition pattern is especially visible among earlier imaging and workflow startups. New companies keep entering Healthcare AI while established players absorb parts of the previous generation.

Is Healthcare AI funding concentrated in a few startups?

Very much so. A small group of Healthcare AI companies has captured billions of dollars while most startups in the dataset remain below $500 million.

The gap has widened lately because a single financing can completely change the distribution. Isomorphic Labs added $2.1 billion in one round. Xaira arrived with roughly $1 billion from the start. Chai Discovery added $400 million in its Series C.

Further down the ranking, companies such as Qure.ai, Nabla, Proscia, Nym, Corti and Causaly sit around the $90 million to $130 million range. Those are substantial venture-backed businesses, yet Isomorphic has raised more than twenty times as much as several of them.

This is a heavily top-loaded market rather than one where funding is spread evenly across dozens of competitors.

Are Healthcare AI startups outside the US raising serious money?

Yes. The US still produces many of the most funded Healthcare AI companies, but several of the market's largest financings now belong to businesses founded or headquartered elsewhere.

UK-based Isomorphic Labs is the obvious example at roughly $2.7 billion. XtalPi, founded by Chinese scientists and operating across China and the US, has raised around $1.3 billion and listed in Hong Kong. South Korea's Lunit has accumulated hundreds of millions of dollars around cancer-imaging AI.

Europe has several other sizeable companies. Switzerland's SOPHiA GENETICS is publicly listed. France has Owkin and Aqemia in AI drug discovery. Sweden's Tandem Health recently raised $100 million while expanding across 14 European markets. Denmark's Corti has raised more than $90 million around clinical conversation AI. New rounds outside the United States are one of the signals we track and update every quarter in our report on healthcare AI.

India-founded Qure.ai has also raised more than $100 million for medical imaging. Healthcare AI capital remains heavily connected to American investors, but the companies themselves are increasingly international.

Company	Home market	Approx. funding	Focus
Isomorphic Labs	United Kingdom	~$2.7B	Drug discovery
XtalPi	China / US	~$1.3B	Drug discovery
Lunit	South Korea	~$591M	Cancer imaging
SOPHiA GENETICS	Switzerland	~$570M+	Precision medicine
Owkin	France / US	~$304M	Drug discovery
Tandem Health	Sweden	~$160M	Clinical assistant
Qure.ai	India / US	~$121M	Radiology AI
Aqemia	France	~$110M	Drug discovery
Corti	Denmark	~$92M	Clinical conversation AI

What types of Healthcare AI startups attract the most funding?

AI drug discovery attracts the most capital by far, while clinical workflow AI has become the strongest software funding cluster.

The drug group alone contains Isomorphic Labs, Relay Therapeutics, XtalPi, Xaira Therapeutics, Exscientia, Chai Discovery, Formation Bio, Generate:Biomedicines, BenevolentAI, Insilico Medicine, Pathos AI, Recursion, Valo Health, Owkin and several smaller companies. No other Healthcare AI segment has so many businesses that have raised hundreds of millions of dollars.

Clinical workflow AI is developing a different kind of funding cluster around Commure, Abridge, OpenEvidence, Innovaccer, Hippocratic AI, Ambience, AKASA, Cohere Health, Qventus, Tandem Health, Nabla and others. These companies can normally reach revenue much earlier than a drug developer, so investors are funding expansion rather than waiting for a molecule to survive clinical trials.

Medical imaging remains a sizeable third category, but much of its funding was accumulated over a longer period. Clinical-trial AI and healthcare data platforms form another meaningful layer below it.

There has also been a clear shift toward generative products. Chai Discovery and Generate:Biomedicines design molecules or proteins. Abridge, Ambience, Nabla, Corti and Tandem work with clinical conversations and medical language. Hippocratic AI is building patient-facing healthcare agents. OpenEvidence generates answers for clinicians from medical literature. Predictive AI is still everywhere in healthcare, but investors are paying far more attention now to systems that can generate, reason and act inside clinical or scientific workflows.

So which Healthcare AI startups are really the most funded today?

Isomorphic Labs is the clear funding leader today, and the bigger story is that AI drug discovery has pulled far ahead of every other Healthcare AI category in raw capital raised.

Roughly $2.7 billion of external funding puts Isomorphic in its own tier. Relay Therapeutics follows around $1.7 billion, while XtalPi, Freenome, Tempus, Commure and Xaira form the next broad billion-dollar group depending on exactly which eligible equity transactions are included.

Below them, Healthcare AI splits into two very different races. Drug companies such as Chai Discovery, Formation Bio and Pathos AI are raising hundreds of millions to finance long scientific and clinical programs. Clinical AI companies such as Abridge, OpenEvidence, Aidoc, Ambience and Tandem Health are raising large rounds while already expanding across doctors, hospitals and health systems.

The distinction is the cleanest way to read the ranking. The largest funding total belongs to the biggest capital bet, not automatically to the company with the largest installed user base or the strongest commercial business. As of now, investors have placed their biggest Healthcare AI bets on the idea that AI can materially change how drugs are discovered and developed.